BPC-157 Peptide: FDA Status, Safety Signals, and Anti-Doping Rules (Research Context)
BPC-157 Peptide: FDA Status, Safety Signals, and Anti-Doping Rules (Research Context)
Quick answers
- FDA-approved? No. FDA lists BPC-157 in Category 2 (compounding safety-risk context).
- Banned in sport? USADA states it is prohibited under WADA (S0: Unapproved Substances).
- Human evidence? Limited; a registered Phase I study does not establish effectiveness for conditions.
What regulators and major organizations say
FDA: Category 2 compounding safety-risk context
FDA maintains a list of bulk drug substances that may present significant safety risks for compounding (Category 2), which includes BPC-157.
USADA/WADA: prohibited for tested athletes
USADA states BPC-157 is prohibited under the WADA Prohibited List category S0 (Unapproved Substances).
OPSS: “unapproved drug” and not in FDA Approved Drugs database
OPSS notes BPC-157 is not in FDA’s Approved Drugs database and is listed on WADA’s Prohibited List (S0).
What “limited human evidence” actually means
Online claims often exceed what human clinical data can support. A trial registration can exist without proving real-world benefit.
Related reading (deeper science)
For a pathway-focused research overview (angiogenesis/inflammation/tissue repair signaling), see: BPC-157: Potential Interactions with Angiogenesis, Inflammation Signaling, and Tissue Repair Pathways .
FAQ
Do you provide dosage or injection instructions?
No. We do not publish dosing or administration instructions.
Is BPC-157 FDA-approved?
No. See FDA references below.